In short
A groundbreaking clinical trial is underway to assess the safety, tolerability, and potential anti-tumor effects of TNG462, a new drug designed for patients with advanced or metastatic solid tumors that have a specific genetic deletion called MTAP. This study combines TNG462, taken orally, with an established immunotherapy drug, pembrolizumab, to explore its effectiveness in various types of cancers.
At a glance
- Drug Name
- TNG462
- Drug Type
- Selective PRMT5 inhibitor
- Administration
- Oral
- Target Patients
- Those with MTAP-deleted advanced or metastatic solid tumors
- Study Design
- Phase 1/2, multi-center, open-label
- Study Phases
- Phase 1: Dose escalation, Phase 2: Dose expansion
- Combination Therapy
- TNG462 alone and with pembrolizumab
- Cancer Types Studied
- NSCLC, Mesothelioma, Pancreatic Ductal Adenocarcinoma, Sarcoma, Other solid tumors
- Primary Outcomes
- Maximum Tolerated Dose, Dosing Schedule, Anti-neoplastic Activity
- Secondary Outcomes
- Safety profile, Pharmacokinetics, SDMA levels in tumor tissue
What is TNG462?
TNG462 is a new drug currently being studied for its potential to treat certain types of cancer. It is described as a selective PRMT5 inhibitor, which means it targets a specific protein in cancer cells. This drug is taken orally, which means patients can swallow it as a pill or liquid, making it more convenient than some cancer treatments that require injections or infusions.
How Does TNG462 Work?
TNG462 works by inhibiting (blocking) a protein called PRMT5. This protein is often overactive in certain types of cancer cells, especially those with a specific genetic change called an MTAP deletion. By blocking PRMT5, TNG462 may be able to slow down or stop the growth of cancer cells without affecting healthy cells as much as some other cancer treatments.
What Conditions Does TNG462 Treat?
TNG462 is being studied for the treatment of advanced or metastatic solid tumors that have an MTAP deletion. Solid tumors are abnormal masses of tissue that don't contain cysts or liquid areas. "Advanced" means the cancer is in a later stage, and "metastatic" means it has spread from where it started to other parts of the body. The clinical trial is focusing on several specific types of cancer:
- Non-small cell lung cancer (NSCLC): Both squamous and non-squamous types
- Mesothelioma: A type of cancer that affects the lining of the lungs, chest wall, or abdomen
- Pancreatic ductal adenocarcinoma: The most common type of pancreatic cancer
- Sarcoma: Cancers that develop in bones or soft tissues
- Other solid tumors with MTAP deletion
Clinical Trial Overview
The clinical trial for TNG462 is a Phase 1/2 study, which means it's in the early stages of testing in humans. This trial is described as "first in human," indicating that it's the first time this drug is being tested in people. The study plans to enroll up to 159 participants with advanced or metastatic solid tumors that have an MTAP deletion.
Trial Phases and Objectives
The trial is divided into two main phases:
- Phase 1 (Dose Escalation): This phase aims to determine the safest and most effective dose of TNG462. Researchers will gradually increase the dose to find the maximum tolerated dose (MTD) and establish a dosing schedule.
- Phase 2 (Dose Expansion): In this phase, researchers will further evaluate the effectiveness of TNG462 at the dose determined in Phase 1. This phase includes five separate groups (or "arms") for different types of MTAP-deleted tumors.
Safety and Effectiveness Measures
Throughout the trial, researchers will be monitoring several aspects of TNG462's performance:
- Safety and tolerability: They will track the frequency and severity of side effects (adverse events).
- Anti-tumor activity: Using imaging techniques, they will assess whether tumors shrink or stop growing in response to the treatment.
- Pharmacokinetics: This involves studying how the drug moves through the body, including how quickly it's absorbed, how long it stays in the system, and how it's eliminated.
- Biomarker analysis: Researchers will measure levels of a substance called SDMA in tumor tissue before and after treatment, which may help indicate how well the drug is working.
Who Can Participate?
This trial is specifically for patients with solid tumors that have a confirmed homozygous MTAP deletion. This means that both copies of the MTAP gene in the tumor cells are missing. Participants must have advanced or metastatic cancer, which typically means that previous treatments have not been successful in controlling the disease.
It's important to note that this is an ongoing clinical trial, and TNG462 is not yet approved for general use. If you think you might be eligible for this trial, you should discuss it with your oncologist or healthcare provider. They can provide more information about the potential risks and benefits, and help determine if this trial might be appropriate for your specific situation.